Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
How to install the free iOS 17 developer beta
Stanford, Cal and SMU to join Atlantic Coast Conference
Score a refurbished MacBook Pro for under $500
Is MrBeast getting married? YouTube King reveals wedding plans with girlfriend Thea Booysen on livestream
Melanie Martinez fans left disappointed with "interactive photo experience" for VIP guests
Is MrBeast collaborating with 'Stumble Guys'? YouTuber drops hints, says 'the game is perfect platform for my creativity'
Lemon8 is the anti-BeReal with all the same problems
US judge pauses Microsoft's Activision buy